The user experienced significant hair regrowth and improved hair health after 5 months of using 0.5mg finasteride and 2.5mg minoxidil daily, with only minor side effects like reduced libido. The user is optimistic about achieving over 90% regrowth and may not need a hair transplant.
Switching from finasteride to dutasteride for hair loss yields mixed results, with some users experiencing improvements and others facing worsening conditions or side effects like shedding. Patience is advised as dutasteride may take longer to show results, and combining treatments is suggested by some users.
The conversation advises against waiting for future hair loss treatments and suggests using proven treatments like Finasteride and Minoxidil. Some users regret not starting treatment earlier, while others discuss the effectiveness and safety of current treatments and the potential of microneedling.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The conversation is about someone using topical finasteride and minoxidil for 7 months, seeing some hair regrowth, and now switching to oral dutasteride. Some suggest continuing treatment and possibly adding a hair transplant in the future.
The original poster believes shaving his head made him more attractive to a specific group of women, despite being less attractive overall. The conversation includes various opinions on attractiveness, with some agreeing that being bald can work for certain men, while others suggest maintaining hair is generally more appealing.
Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
User shared 6-month progress using Fin, Min, Microneedling, Biotin, and Ketoconazole Shampoo for hair loss. They microneedle once a week, use 1.25 mg Fin daily, and apply topical Min twice a day.
Hairfolliclestem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfolliclestem cells and increase hairgrowth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Hair loss is linked to the loss of stem cells in hairfollicles, and potential treatments include gene editing and microneedling. Discussions also mention using Minoxidil, finasteride, and dermarolling to improve hairgrowth.
PP405 targets hairfolliclestem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
Hairfollicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
Hairfollicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
PP405 cannot restore extracted hairfollicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
PP405 is being discussed as a potential new approach to hair loss by targeting folliclestem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hairfolliclestem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
PP405 may revive dormant hairfollicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
Adipose fat cells and stem cells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hairgrowth.
Redensyl is a plant-based treatment that may support hair regrowth by reactivating dormant follicles and improving hair density, especially in early-stage thinning. It is not a miracle cure and results vary; it is less proven than Minoxidil or Finasteride and may cause scalp irritation.
Cold shock therapy may promote hairgrowth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.
PP405 shows promise for reactivating hairfollicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
JW0061 shows superior hairgrowth results compared to existing treatments, with significant increases in hairfollicles. The Wnt/β-catenin pathway is crucial for hairgrowth, and JW0061 activates this pathway effectively.
Testosterone can still cause hair loss even when DHT is blocked by dutasteride, especially if hairfollicles are sensitive. Topical treatments like RU58841 or pyrilutamide may help, but their long-term effectiveness is uncertain compared to dutasteride.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hairfollicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.